Wedbush Raises Price Target on Tyra Bioscience to $53 From $37, Keeps Outperform Rating

robot
Abstract generation in progress

Wedbush has increased its price target for Tyra Bioscience to $53 from $37, while maintaining an “Outperform” rating on the stock. This adjustment reflects a more optimistic outlook by the analyst firm for the biotechnology company. The article also lists various other analyst actions and company news related to Tyra Biosciences over recent months.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)